Literature DB >> 6643767

Vitiligo in patients with metastatic melanoma: a good prognostic sign.

J J Nordlund, J M Kirkwood, B M Forget, G Milton, D M Albert, A B Lerner.   

Abstract

We have identified and studied twenty-seven patients with melanoma who also had vitiligo. Four patients had vitiligo before the diagnosis of melanoma, and twenty-three developed depigmentation after the diagnosis of malignancy. We also have reviewed published reports about twenty-four other patients with melanoma who developed vitiligo. The clinical course of the melanoma in the fifty-one patients was remarkably similar. Thirty-seven had a melanoma arising at a site which tends to carry a poor prognosis, for example, on the trunk, under the nail, or on the mucous membranes. Forty-nine patients had metastases in regional lymph nodes or at distal sites. Thirty-three patients survived 5 years, and twenty-five survived 10 years. These data suggest that the appearance of vitiligo in patients with metastatic melanoma portends a longer survival than expected. The patients with vitiligo are not necessarily cured and eventually may succumb to metastatic disease. We were unable to determine whether the vitiligo caused retardation of tumor growth or whether the melanoma caused vitiligo.

Entities:  

Mesh:

Year:  1983        PMID: 6643767     DOI: 10.1016/s0190-9622(83)70182-9

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  74 in total

Review 1.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Michal T Krauze; Ahmad Tarhini; Helen Gogas; John M Kirkwood
Journal:  Semin Immunopathol       Date:  2011-01-31       Impact factor: 9.623

2.  Melanoma vaccines: clinical status and immune endpoints.

Authors:  Deena M Maurer; Lisa H Butterfield; Lazar Vujanovic
Journal:  Melanoma Res       Date:  2019-04       Impact factor: 3.599

Review 3.  [Vitiligo. Diagnosis, differential diagnosis, and current patient management].

Authors:  A Hartmann
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751

Review 4.  Melanoma-associated leukoderma - immunology in black and white?

Authors:  Hadas Prag Naveh; Uma N M Rao; Lisa H Butterfield
Journal:  Pigment Cell Melanoma Res       Date:  2013-10-09       Impact factor: 4.693

5.  Progression of Cutaneous Vitiligo in a Patient with Large Posterior Choroidal Melanoma: A Case Report.

Authors:  Angela Ding; Javier Elizalde; Rafael Ignacio Barraquer
Journal:  Ocul Oncol Pathol       Date:  2015-04-01

6.  Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.

Authors:  Katelyn T Byrne; Peisheng Zhang; Shannon M Steinberg; Mary Jo Turk
Journal:  J Immunol       Date:  2014-01-08       Impact factor: 5.422

7.  Prevalence of choroidal nevus and retinal pigment epithelial alterations in vitiligo patients.

Authors:  Efrat Fleissig; Mor Pavlovksy; Anat Loewenstein; Dinah Zur; Hadas Newman; Shay Keren; Dafna Goldenberg; Efrat Bar-Ilan; Michaella Goldstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-16       Impact factor: 3.117

8.  Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Authors:  Jason R Baird; Katelyn T Byrne; Patrick H Lizotte; Seiko Toraya-Brown; Uciane K Scarlett; Matthew P Alexander; Mee Rie Sheen; Barbara A Fox; David J Bzik; Marcus Bosenberg; David W Mullins; Mary Jo Turk; Steven Fiering
Journal:  J Immunol       Date:  2012-12-07       Impact factor: 5.422

9.  Ocular abnormalities associated with cutaneous melanoma and vitiligolike leukoderma.

Authors:  M A Chang; G Fournier; H K Koh; A J Sober; H Nakagawa; T B Fitzpatrick; D M Albert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

10.  Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism.

Authors:  O Merimsky; Y Shoenfeld; G Yecheskel; S Chaitchik; E Azizi; P Fishman
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.